Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be at least 18 years old
• You have an advanced, spreading, or inoperable solid tumour (not gallbladder cancer or bile duct cancer) that has continued to grow after at least one previous cancer treatment, and no other proven treatment options are available — or you have breast cancer or stomach/oesophageal cancer that has previously been treated with specific HER2-targeted therapies including trastuzumab deruxtecan (T-DXd)
• Your tumour must test strongly positive for a protein called HER2 (scored as IHC 3+), confirmed by the trial's central laboratory
• You must be able to provide a tumour tissue sample for HER2 testing
• You must have at least one measurable area of cancer that can be tracked on scans
• You must be reasonably well and able to carry out daily activities (confirm with trial site regarding the specific fitness score required)
• Your doctor estimates you have a life expectancy of at least 3 months
• If you have had brain tumours in the past, they must have been treated, be stable, and cause no current symptoms, with any radiation treatment completed at least 7 days before starting the trial
• Your liver, kidneys, and other organs must be functioning well enough
• If you are a woman who could become pregnant, you must have a negative pregnancy test before joining
• If you could father or become pregnant, you must be willing to use two forms of contraception during the trial

Who may not be able to join:

• You have cancer that has spread to the lining around the brain or spinal cord, or have untreated brain tumours
• You have serious or uncontrolled heart or blood vessel problems
• You are still experiencing significant side effects from a previous cancer treatment
• You have an infection that is not under control, or you need intravenous antibiotics, antiviral, or antifungal medicines
• You have HIV
• You have an active hepatitis B or C infection
• You currently have an active COVID-19 infection
• You have previously had a serious life-threatening allergic reaction to a type of drug similar to the one used in this trial (confirm with trial site)
• You have a serious medical or mental health condition that would make it difficult to safely receive the treatment
• Your doctor believes there is any other reason participation would not be safe or suitable for you
• You have previously been treated with HER2-targeted therapy (applies to one specific group in the trial only — confirm with trial site)
• You have a recent history of serious injury or major surgery (confirm with trial site for timeframe)
• You have received cancer treatment or any experimental therapy within approximately the last 4 weeks or more before starting the trial
• You have previously received the study drug zanidatamab
• You have colorectal cancer with certain specific gene mutations (KRAS/NRAS or BRAF)
• You have non-small cell lung cancer with certain specific gene changes (ALK, EGFR, or ROS1)
• You are pregnant, breastfeeding, or planning a pregnancy
• You have or have had another separate cancer whose treatment or progression could interfere with this trial, in your doctor's opinion

Important: Always verify eligibility with the trial site directly before applying.